Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized comparison of degarelix three-month depot dosing regimens in prostate cancer
2004-003815-22Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Proportion of patients with testosterone ≤0.5 ng/mL from Day 28 until end of study. Started Dec 2004; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-003815-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003815-22.